Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 25/08/2026			5-day change	1st Jan Change
5.050 ^USD	-3.81%		+26.57%	-1.56%

08-26	Nordic stocks in North America, Ericsson rose 0.6%	FW
08-24	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

63d9b16e9af75f04339897d3b8.2UTNrRVSTa8lXekdFuF9iLkiGgCH_FDjqhfH71p0b8A.jymmyTgUD9dhDZ9kO64rvYkQWVTez2Sz5kGNph0aJ5a_D6yVfDt8nhIwjg~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

08-24	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
08-24	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
03-24	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
03-24	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
12-22	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
11-18	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
11-05	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
11-03	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
11-03	Top Premarket Decliners	MT
11-03	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
11-03	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
14/10/25	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/10/25	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
23/09/25	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/09/25	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/07/25	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/07/25	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
25/07/24	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24/05/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
22/03/24	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT
29/01/24	Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	MT
20/10/23	Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	MT
21/09/23	Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+22.2%
	LONZA GROUP AG					+15.88%
	REVOLUTION MEDICINES, INC.					+7.07%
	BEONE MEDICINES AG					+15%
	IQVIA HOLDINGS INC.					+5.22%
	CELLTRION, INC.					+37.56%
	MEDPACE HOLDINGS, INC.					-6.01%
	ASCENDIS PHARMA A/S					+26%
	EUROFINS SCIENTIFIC SE					-0.4%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-4.78%
	Average					+11.77%
	Weighted average by Cap.					+12.64%